Update shared on 04 Nov 2025
Fair value Increased 2.27%Analysts have raised their price target for Fosun International from $5.54 to $5.67, citing updated evaluations of future profitability and expectations for stronger valuation metrics, even though revenue growth and profit margin forecasts are modestly lower.
What's in the News
- A special shareholders meeting is scheduled for October 23, 2025, with a vote on the adoption of the 2025 H share RSU scheme for Fosun Pharma and authorization for directors to implement the plan (Key Developments).
- The company completed a buyback of 41,310,000 shares, totaling 0.51 percent of outstanding shares, for HKD 169.82 million as of June 5, 2025, under the buyback program announced in August 2024 (Key Developments).
- An upcoming board meeting is set for August 27, 2025, to review interim results for the first half of the year and to consider the payment of an interim dividend (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from HK$5.54 to HK$5.67. This reflects updated expectations for the company's fair value.
- Discount Rate remains virtually unchanged, holding steady at approximately 12.89%.
- Revenue Growth projection has fallen modestly, decreasing from 7.49% to 6.72%.
- Net Profit Margin estimate has declined somewhat, from 2.81% to 2.49%.
- Future P/E ratio forecast has increased, rising from 9.33x to 11.02x. This signals expectations for stronger valuation metrics.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.